ONIVYDE

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Estonia, Finland, France, Ireland, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, UK.

Active ingredients

The drug ONIVYDE contains one active pharmaceutical ingredient (API):

1	Irinotecan UNII 042LAQ1IIS - IRINOTECAN HYDROCHLORIDE
	Irinotecan is a semi-synthetic derivative of camptothecin. It is an antineoplastic agent which acts as a specific inhibitor of DNA topoisomerase I.
	Read more about Irinotecan

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01CE02	Irinotecan	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CE Topoisomerase 1 (TOP1) inhibitors
Discover more medicines within L01CE02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02467135
EE	Ravimiamet	1730911, 1849934
FI	Lääkealan turvallisuus- ja kehittämiskeskus	464326
FR	Base de données publique des médicaments	63390752
GB	Medicines & Healthcare Products Regulatory Agency	341034
IT	Agenzia del Farmaco	045168010
JP	医薬品医療機器総合機構	4240404A3027
LT	Valstybinė vaistų kontrolės tarnyba	1081458
NL	Z-Index G-Standaard, PRK	137677
NZ	Medicines and Medical Devices Safety Authority	18210
PL	Rejestru Produktów Leczniczych	100381714
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66173001
SG	Health Sciences Authority	15397P
US	FDA, National Drug Code	15054-0043